Comorbidities should be factor in prostate biopsy choice, UCI study finds
UC Irvine Health urologists and health policy experts report in a new study that two written assessments that identify existing comorbidities – the patient-reported Total Illness Burden Index for Prostate Cancer (TIBI-Cap) and the physician-reported Charlson Comorbidity Index – can successfully target prostate patients who would not benefit from biopsy to discover possible cancer.
The authors say that by taking comorbidities into factor, it may not be necessary for men to have prostate biopsy. This study does not preclude the use of PSA screening, but it does set the ...